Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer

NCT00043862 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00043862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00043862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2002
Completion date
Not reported
Enrollment
60 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, small cell, small cell lung cancer